Cargando…
Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials
The diabetes epidemic continues to grow unabated, with a staggering toll in micro- and macrovascular complications, disability, and death. Diabetes causes a two- to fourfold increase in the risk of cardiovascular disease, and represents the first cause of dialysis treatment both in the UK and the US...
Autores principales: | Reboldi, Gianpaolo, Gentile, Giorgio, Angeli, Fabio, Verdecchia, Paolo |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686259/ https://www.ncbi.nlm.nih.gov/pubmed/19475778 |
Ejemplares similares
-
Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension
por: Angeli, Fabio, et al.
Publicado: (2021) -
The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction
por: Verdecchia, Paolo, et al.
Publicado: (2008) -
Hypertension and myocarditis following COVID-19 vaccination. Two sides of the coin?()
por: Angeli, Fabio, et al.
Publicado: (2023) -
Diuretic Treatment of Hypertension
por: Grossman, Ehud, et al.
Publicado: (2011) -
COVID-19, vaccines and deficiency of ACE(2) and other angiotensinases. Closing the loop on the "Spike effect"
por: Angeli, Fabio, et al.
Publicado: (2022)